With 0.57 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.06 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $5.065 whereas the lowest price it dropped to was $4.73. The 52-week range on MEIP shows that it touched its highest point at $9.00 and its lowest point at $1.46 during that stretch. It currently has a 1-year price target of $22.67. MEIP paid its most recent dividend on 1700092800, while the ex-dividend date for that was 1700092800. Beta for the stock currently stands at 0.38.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of MEIP was down-trending over the past week, with a drop of -5.78%, but this was up by 8.67% over a month. Three-month performance surged to 126.91% while six-month performance rose 79.78%. The stock gained 98.78% in the past year, while it has gained 43.82% so far this year.
Float and Shares Shorts:
At present, 6.66 million MEIP shares are outstanding with a float of 6.59 million shares on hand for trading. On 2025-07-31, short shares totaled 2.15 million, which was 672.0 higher than short shares on 1751241600. In addition to Ms. Nicole Chyoko Iida as the firm’s Vice President of Legal Affairs, Ms. Anne Frese serves as its Chief People Officer.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, MEIP reported revenue of $0.0 and operating income of -$2774000.0. The EBITDA in the recently reported quarter was -$2774000.0 and diluted EPS was -$0.39.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for MEIP since 3 analysts follow the stock currently. There are 0 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 3 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of $3.62 being high and $3.62 being low. For MEIP, this leads to a yearly average estimate of $3.62. The surprise factor in the prior quarter was -$1.26. Based on analyst estimates, the high estimate for the next quarter is $0 and the low estimate is $0. The average estimate for the next quarter is thus $0.
